Rocky Mountain Spotted Fever in Children

Pediatric Clinics of North America

Volumn 60, Issue 2, 2013, Pages 455-470

  Woods, Charles R ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Doxycycline; Increased intracranial pressure; Rash; Rickettsia rickettsii; Rocky mountain spotted fever; Sepsis

Indexed keywords

CEPHALOSPORIN; CHLORAMPHENICOL; DOXYCYCLINE; MACROLIDE; SULFONAMIDE;

ANTIBODY RESPONSE; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM CARRIER; CHILD; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG CHOICE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; GEOGRAPHIC DISTRIBUTION; HOST PATHOGEN INTERACTION; HUMAN; INCIDENCE; INFECTION PREVENTION; LABORATORY TEST; LATEX AGGLUTINATION TEST; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; PROGNOSIS; REVIEW; RICKETTSIA RICKETTSII; ROCKY MOUNTAIN SPOTTED FEVER; SEROLOGY; SEROPREVALENCE; THERAPY DELAY;

ANIMALS; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; DISEASE VECTORS; DOXYCYCLINE; HUMANS; PROGNOSIS; RICKETTSIA RICKETTSII; ROCKY MOUNTAIN SPOTTED FEVER; SHOCK, SEPTIC; UNITED STATES;

EID: 84875345298     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2012.12.001     Document Type: Review

References (97)

1. Lin L., Decker C.F. Rocky mountain spotted fever. Dis Mon 2012, 58(6):361-369.
2. Spencer R.R. Rocky mountain spotted fever. J Infect Dis 1929, 44:257-276.
3. Tamura A., Ohashi N., Urakami H., et al. Classification of Rickettsia tsutsugamushi in a new genus, Orientia gen. nov., as Orientia tsutsugamushi comb. nov. Int J Syst Bacteriol 1995, 45(3):589-591.
4. Raoult D., Roux V. Rickettsioses as paradigms of new or emerging infectious diseases. Clin Microbiol Rev 1997, 10(4):694-719.
5. Merhej V., Raoult D. Rickettsial evolution in the light of comparative genomics. Biol Rev Camb Philos Soc 2011, 86(2):379-405.
6. Openshaw J.J., Swerdlow D.L., Krebs J.W., et al. Rocky Mountain Spotted Fever in the United States, 2000-2007: interpreting contemporary increases in incidence. Am J Trop Med Hyg 2010, 83(1):174-182.
7. Centers for Disease Control and Prevention. Annual cases of RMSF in the United States. Available at: Accessed October 1, 2012. http://www.cdc.gov/rmsf/stats/index.html.
8. Chen L.F., Sexton D.J. What's new in Rocky Mountain spotted fever. Infect Dis Clin North Am 2008, 22(3):415-432.
9. Hayes S.F., Burgdorfer W. Reactivation of Rickettsia rickettsii in Dermacentor andersonii ticks: an ultrastructural analysis. Infect Immun 1982, 37(2):779-785.
10. Roux V., Drancourt M., Raoult D. Determination of genome sizes of Rickettsia spp. within the spotted fever group, using pulsed-field gel electrophoresis. J Bacteriol 1992, 174(22):7455-7457.
11. Andersson S.G., Kruland C.G. Reductive evolution of resident genomes. Trends Microbiol 1998, 6(7):263-268.
12. Audia J.P., Winkler H.H. Study of the five Rickettsii prowazekii proteins annotated as ATP/ADP translocases (Tlc): only Tlc1 transports ATP/ADP, while Tlc4 and Tlc5 transport other ribonucleotides. J Bacteriol 2006, 188(17):6261-6268.
13. Riley S.P., Goh K.C., Hermanas T.M., et al. The Rickettsia conorii autotransporter protein Sca1 promotes adherence to nonphagocytic mammalian cells. Infect Immun 2010, 78(5):1895-1904.
14. Carmichael J.R., Fuerst P.A. A rickettsial mixed infection in a Dermacentor variabilis tick from Ohio. Ann N Y Acad Sci 2006, 1078:334-337.
15. McDade J.E., Newhouse V.F. Natural history of Rickettsia rickettsii. Annu Rev Microbiol 1986, 40:287-309.
16. Allan S.A. Ticks (Class Arachnida; Order Acarina). Parasitic diseases of wild mammals 2001, 72-106. Iowa State University Press, Ames (IA). W.M. Samuel, M.J. Pybus, A.A. Kocan (Eds.).
17. Stromdahl E.Y., Jiang J., Vince M., et al. Infrequency of Rickettsia rickettsii in Dermacentor variabilis removed from humans, with comments on the role of other human-biting ticks associated with spotted fever group Rickettsiae in the United States. Vector Borne Zoonotic Dis 2001, 11(7):969-977.
18. Burgdorfer W., Brinton L.P. Mechanisms of transovarial infection of spotted fever Rickettsiae in ticks. Ann N Y Acad Sci 1975, 266:61-72.
19. Fritzen C.M., Huang J., Westby K., et al. Infection prevalences of common tick-borne pathogens in adult lone star ticks (Amblyomma americanum) and American dog ticks (Dermacentor variabilis) in Kentucky. Am J Trop Med Hyg 2011, 85(4):718-723.
20. Demma L.J., Traeger M.S., Nicholson W.L., et al. Rocky Mountain Spotted Fever from an unexpected tick vector in Arizona. N Engl J Med 2005, 353(6):587-594.
21. Chapman A.S., Bakken J.S., Folk S.M., et al. Diagnosis and management of tickborne rickettsial diseases: rocky mountain spotted fever, Ehrlichiosis, and Anaplasmosis-United States. A practical guide for physicians and other health-care and public health professionals. MMWR Morb Mortal Wkly Rep 2006, 55(RR04):1-27.
22. Breitschwerdt E.B., Hegarty B.C., Maggi R.G., et al. Rickettsia rickettsii transmission by a lone star tick, North Carolina. Emerg Infect Dis 2011, 17(5):873-875.
23. Smith M.P., Ponnusamy L., Jiang J., et al. Bacterial pathogens in ixodid ticks from a piedmont county in North Carolina: prevalence of rickettsial organisms. Vector Borne Zoonotic Dis 2010, 10(10):939-952.
24. Wells G.M., Woodward T.E., Fiset P., et al. Rocky mountain spotted fever caused by blood transfusion. JAMA 1978, 239(26):2763-2765.
25. Sexton D.J., Gallis H.A., McRae J.R., et al. Letter: possible needle-associated Rocky Mountain spotted fever. N Engl J Med 1975, 292(12):645.
26. Walker D.H., Valbuena G.A., Olano J.P. Pathogenic mechanisms of diseases caused by Rickettsia. Ann N Y Acad Sci 2003, 990:1-11.
27. Tamrakar S.B., Haas C.N. Dose-response model of Rocky Mountain spotted fever (RMSF) for Human. Risk Anal 2011, 31(10):1610-1621.
28. D'Angelo L.J., Winkler W.G., Bregman D.J. Rocky Mountain Spotted Fever in the United States: 1975-1977. J Infect Dis 1978, 138(2):273-276.
29. Centers for Disease Control and Prevention Consequences of delayed diagnosis of Rocky Mountain Spotted Fever in children-West Virginia, Michigan, Tennessee, and Oklahoma, May-July 2000. MMWR Morb Mortal Wkly Rep 2000, 49(39):885-888.
30. Centers for Disease Control and Prevention Summary of notifiable diseases-United States, 2010. MMWR Morb Mortal Wkly Rep 2012, 59(53):1-116.
31. Marshall G.S., Stout G.G., Jacobs R.F., et al. Antibodies reactive to Rickettsia rickettsii among children in the southeast and south central regions of the United States. Arch Pediatr Adolesc Med 2003, 157(5):443-448.
32. Demma L.J., Traeger M., Blau D., et al. Serologic evidence for exposure to Rickettsia rickettsii in eastern Arizona and recent emergence of Rocky Mountain spotted fever in this region. Vector Borne Zoonotic Dis 2006, 6(4):432-439.
33. Buckingham S.C., Marshall G.S., Schutze G.E., et al. Clinical and laboratory features, hospital course, and outcome of Rocky Mountain Spotted Fever in children. J Pediatr 2007, 150(2):180-184.
34. Salgo M.P., Telsak E., Currie B., et al. A focus of Rocky Mountain spotted fever within New York City. N Engl J Med 1988, 318(21):1345-1348.
35. Centers for Disease Control and Prevention Fatal cases of Rocky Mountain Spotted Fever in family clusters-three states, 2003. MMWR Morb Mortal Wkly Rep 2004, 53(19):407-410.
36. Paddock C.D., Brenner O., Vaid C., et al. Short report: concurrent Rocky Mountain spotted fever in a dog and its owner. Am J Trop Med Hyg 2002, 66(2):197-199.
37. Walker D.H., Kirkman H.N. Rocky Mountain spotted fever and deficiency in glucose-6-phosphate dehydrogenase. J Infect Dis 1980, 142:771.
38. Walker D.H. The role of host factors in the severity of spotted fever and typhus rickettsioses. Ann N Y Acad Sci 1990, 590:10-19.
39. Helmick C.G., Bernard K.W., D'Angelo L.J. Rocky Mountain spotted fever: clinical, laboratory, and epidemiological features of 262 cases. J Infect Dis 1984, 150(4):480-488.
40. McDade J.E. Diagnosis of rickettsial diseases: a perspective. Eur J Epidemiol 1991, 7(3):270-275.
41. Mansueto P., Vitale G., Di Lorenzo G., et al. Immunology of human rickettsial diseases. J Biol Regul Homeost Agents 2008, 22(2):131-139.
42. Rydkina E., Sahni S.K., Santucci L.A., et al. Selective modulation of antioxidant enzyme activities in host tissues during Rickettsia conorii infection. Microb Pathog 2004, 36(6):293-301.
43. Walker D.H. Rickettsiae and Rickettsial infections: the current state of knowledge. Clin Infect Dis 2007, 45(Suppl 1):S39-S44.
44. Valbuena G., Feng H.M., Walker D.H. Mechanisms of immunity against rickettsiae: new perspectives and opportunities offered by unusual intracellular parasite. Microbes Infect 2002, 4(6):625-633.
45. Bradford W.D., Hawkins H.K. Rocky mountain spotted fever in childhood. Am J Dis Child 1977, 131(11):1228-1232.
46. Elgetany M.T., Walker D.H. Hemostatic changes in Rocky mountain spotted fever and Mediterranean spotted fever. Am J Clin Pathol 1999, 112(2):159-168.
47. Schmaier A.H., Srikanth S., Elghetany M.T., et al. Hemostatic/fibrinolytic protein changes in C3H/HeN mice infected with Rickettsia conorii-a model for Rocky Mountain spotted fever. Thromb Haemost 2001, 86(3):871-879.
48. Martinez J.J., Seveau S., Velga E., et al. Ku70, a component of DNA-dependent protein kinase, is a mammalian receptor for Rickettsia conorii. Cell 2005, 123(6):1013-1023.
49. Chan Y.G., Riley S.P., Martinez J.J. Adherence to and invasion of host cells by spotted fever group Rickettsia species. Front Microbiol 2010, 1:139. 10.3389/fmicb.2010.00139.
50. Martinez J.J., Cossart P. Early signaling events involved in the entry of Rickettsia conorii into mammalian cells. J Cell Sci 2004, 117(Pt 21):5097-5106.
51. Chan Y.G., Cardwell M., Hermanas T.M., et al. Rickettsial outer-membrance protein B (rOmpB) mediates bacterial invasion through Ku70 in an actin, c-Cbl, clathrin and caveolin 2-dependent manner. Cell Microbiol 2009, 11(4):629-644.
52. Heinzen R.A. Rickettsial actin-based motility. Behavior and involvement of cytoskeletal regulators. Ann N Y Acad Sci 2003, 990:535-547.
53. Gouin E., Welch M.D., Cossart P. Actin-based motility of intracellular pathogens. Curr Opin Microbiol 2005, 8:35-45.
54. Gong B., Ma L., Liu Y., et al. Rickettsiae induce microvascular hyperpermeability via phosphorylation of VE-cadherins: evidence from atomic force microscopy and biochemical studies. PLoS Negl Trop Dis 2012, 6(6):e1699.
55. Woods M.E., Olano J.P. Host defenses to Rickettsia rickettsii infection contribute to increased microvascular permeability in human cerebral endothelial cells. J Clin Immunol 2008, 28:174-185.
56. Spencer R., Parker R. Rocky Mountain spotted fever: infectivity of fasting and recently fed ticks. Public Health Rep 1923, 38:333-339.
57. Thorner A.R., Walker D.H., Petri W.A. Rocky mountain spotted fever. Clin Infect Dis 1998, 27(6):1353-1359. [quiz: 60].
58. DuPont H.L., Hornick R.B., Dawkins A.T., et al. Rocky Mountain spotted fever: a comparative study of the active immunity induced by inactivated and viable pathogenic Rickettsia rickettsii. J Infect Dis 1973, 128(3):340-344.
59. Joshi S.G., Francis C.W., Silverman D.J., et al. NF-κB activation suppresses host cell apoptosis during Rickettsia rickettsii infection via regulatory effects on intracellular localization of levels of apoptogenic and anti-apoptogenic proteins. FEMS Microbiol Lett 2004, 234(2):333-341.
60. Rydkina E., Turpin L.C., Sahni S.K. Rickettsia rickettsii infection of human macrovascular and microvascular endothelial cells reveals activation of both common and cell type-specific host response mechanisms. Infect Immun 2010, 78(6):2599-2606.
61. Walker D.H., Olano J.P., Feng H.M. Critical role of cytotoxic T lymphocytes in immune clearance of rickettsial infection. Infect Immun 2001, 69:1841-1846.
62. Feng H.M., Whitworth T., Olano J.P., et al. Fc-dependent polyclonal antibodies and antibodies to outer membrane proteins A and B, but not to lipopolysaccharide, protect SCID mice against fatal Rickettsia conorii infection. Infect Immun 2004, 72(4):2222-2228.
63. Chan Y.G., Riley S.P., Chen E., et al. Molecular basis of immunity to rickettsial infection conferred through outer membrane protein B. Infect Immun 2011, 79(6):2303-2313.
64. Carpenter C.F., Gandhi T.K., Kong L.K., et al. The incidence of ehrlichial and rickettsial infection in patients with unexplained fever and recent history of tick bite in central North Carolina. J Infect Dis 1999, 180(3):900-903.
65. Minninear T.D., Buckingham S.C. Managing Rocky Mountain spotted fever. Expert Rev Anti Infect Ther 2009, 7(9):1131-1137.
66. Dalton M.J., Clarke M.J., Holman R.C., et al. National surveillance for Rocky Mountain spotted fever, 1981-1992: epidemiologic summary and evaluation of risk factors for fatal outcome. Am J Trop Med Hyg 1995, 52(5):405-413.
67. Treadwell T.A., Holman R.C., Clarke M.J., et al. Rocky Mountain spotted fever in the United States, 1993-1996. Am J Trop Med Hyg 2000, 63(1-2):21-26.
68. Kirk J.L., Fine D.P., Sexton D.J., et al. Rocky Mountain spotted fever. Clinical review based on 48 confirmed cases, 1943-1986. Medicine 1990, 69(1):35-45.
69. Haynes R.E., Sanders D.Y., Cramblett H.G. Rocky Mountain spotted fever in children. J Pediatr 1970, 76(5):685-693.
70. Davis A.E., Bradford W.D. Abdominal pain resembling acute appendicitis in Rocky Mountain spotted fever. JAMA 1982, 247(20):2811-2812.
71. Kirkland K.B., Marcom P.K., Sexton D.J., et al. Rocky Mountain spotted fever complicated by gangrene: report of six cases and review. Clin Infect Dis 1993, 16(5):629-634.
72. Centers for Disease Control and Prevention. Rocky Mountain spotted fever. Symptoms, diagnosis and treatment. Available at: Accessed October 1, 2012. http://www.cdc.gov/rmsf/symptoms/index.html.
73. Bradford W.D., Hackel D.B. Myocardial involvement in Rocky Mountain spotted fever. Arch Pathol Lab Med 1978, 102(7):357-359.
74. Maller V.G., Agarwal A.K., Choudhary A.K. Diffusion imaging findings in Rocky Mountain spotted fever encephalitis: a case report. Emerg Radiol 2012, 19(1):79-81.
75. Crapp S., Harrar D., Strother M., et al. Rocky Mountain spotted fever: 'starry sky' appearance with diffusion-weighted imaging in a child. Pediatr Radiol 2012, 42(4):499-502.
76. Raoult D., Paddock C.D. Rickettsia parkeri infection and other spotted fevers in the United States. N Engl J Med 2005, 353(6):626-627.
77. Clements M.L., Dumler J.S., Fiset P., et al. Serodiagnosis of Rocky Mountain spotted fever: comparison of IgM and IgG enzyme-linked immunosorbent assay and indirect fluorescent antibody test. J Infect Dis 1983, 148(5):876-880.
78. Kovacova E., Kazar J. Rickettsial diseases and their serological diagnosis. Clin Lab 2000, 45(5-6):239-245.
79. Walker D.H. Rocky Mountain spotted fever: a seasonal alert. Clin Infect Dis 1995, 20(5):1111-1117.
80. Centers for Disease Control and Prevention. In-depth information-Rocky Mountain Spotted Fever (RMSF). Available at: Accessed October 1, 2012. http://www.cdc.gov/rmsf/info/index.html.
81. Schutze G.E., Buckingham S.C., Marshall G.S., et al. Human monocytic ehrlichiosis in children. Pediatr Infect Dis J 2007, 26(6):475-479.
82. Jacobs R.F., Schutze G.E. Ehrlichiosis in children. J Pediatr 1997, 131(2):184-192.
83. Ferrari F.A., Goddard J., Paddock C.D., et al. Rickettsia parkeri and Candidatus Rickettsia andeanae in Gulf Coast tics, Mississippi, USA. Emerg Infect Dis 2012, 18(10):1705-1707.
84. American Academy of Pediatrics Rocky mountain spotted fever. Red book: 2012 report of the committee on infectious diseases 2012, 623-625. American Academy of Pediatrics, Elk Grove Village (IL). 29th edition. L.K. Pickering (Ed.).
85. Lochary M.E., Lockhart P.B., Williams W.T. Doxycycline and staining of permanent teeth. Pediatr Infect Dis J 1998, 17(5):429-431.
86. Volovitz B., Shkap R., Amir J., et al. Absence of tooth staining with doxycycline treatment in young children. Clin Pediatr 2007, 46(2):121-126.
87. Holman R.C., Paddock C.D., Curns A.T., et al. Analysis of risk factors for fatal Rocky Mountain spotted fever: evidence for superiority of tetracyclines for therapy. J Infect Dis 2001, 184(11):1437-1444.
88. Rolain J.M., Maurin M., Vestris G., et al. In vitro susceptibilities of 27 rickettsiae to 13 antimicrobials. Antimicrob Agents Chemother 1998, 42(7):1537-1541.
89. Harrell G.T. Rocky Mountain spotted fever. Medicine 1949, 28(4):333-370.
90. Topping N.H. Experimental Rocky Mountain spoted fever and endemic typhus treated with prontosil or sulfapyradine. Public Health Rep 1939, 54:1143-1147.
91. Dahlgren F.S., Holman R.C., Paddock C.D., et al. Fatal Rocky Mountain spotted fever in the United States, 1999-2007. Am J Trop Med Hyg 2012, 86(4):713-719.
92. Hattwick M.A., Retailliau H., O'Brien R.J., et al. Fatal Rocky Mountain spotted fever. JAMA 1978, 240(14):1499-1503.
93. Kirkland K.B., Wilkinson W.E., Sexton D.J. Therapeutic delay and mortality in cases of Rocky Mountain spotted fever. Clin Infect Dis 1995, 20(5):1118-1121.
94. Archibald L.K., Sexton D.J. Long-term sequelae of Rocky Mountain spotted fever. Clin Infect Dis 1995, 20(5):1122-1125.
95. American Academy of Pediatrics Prevention of Tickborne Infections. Red book: 2012 report of the committee on infectious diseases 2012, 207-209. American Academy of Pediatrics, Elk Grove Village (IL). 29th edition. L.K. Pickering (Ed.).
96. Centers for Disease Control and Prevention. Preventing tick bites. Available at: Accessed October 1, 2012. http://www.cdc.gov/ticks/avoid/on_people.html.
97. Ellison D.W., Clark T.R., Sturdevant D.E., et al. Genomic comparison of virulent Rickettsia rickettsii Sheila Smith and avirulent Rickettsia rickettsii Iowa. Infect Immun 2008, 76(2):542-550.